{"nctId":"NCT00758420","briefTitle":"Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence","startDateStruct":{"date":"2008-10"},"conditions":["Varicose Veins"],"count":77,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Varisolve (Polidocanol Endovenous Microfoam)"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Agitated Saline"]}],"interventions":[{"name":"Varisolve (Polidocanol Endovenous Microfoam)","otherNames":[]},{"name":"Agitated Saline","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and Females 18-65 years old\n* VEINES Sym Score less than 75 points\n* Varicose Vein clinical classification CEAP 2, 3, 4, or 5\n* Incompetence of SFJ associated with incompetence of the GSV or other major accessory vein\n* Superficial venous disease manifested by both symptoms and visible varicosities\n* Ability to comprehend and sign an informed consent document and completed study questionnaires in English\n\nExclusion Criteria:\n\n* Incompetence of the SSV which substantially contributes to the filling of visible varicose veins\n* Current or previous Deep Vein Thrombosis\n* Leg obesity\n* Peripheral arterial disease in the leg to be treated\n* Reduced mobility\n* Planned prolonged travel with limited mobility with in 4 weeks of treatment\n* History of pulmonary embolism or stroke\n* Major surgery, prolonged hospitalization or pregnancy within 3 months\n* Current anticoagulation therapy (within 7 days of enrollment)\n* Participation in a clinical study involving a investigational product within 3 months\n* Major co-existing disease or clinically significant laboratory abnormalities\n* Known allergic response to polidocanol or heparin or severe and/or multiple allergic reactions\n* Women of childbearing potential not using effective contraception one month prior to enrollment and/or unwilling to continue while on study\n* Pregnant or lactating women\n* Current alcohol or drug abuse","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Absolute Change From Baseline Score for the VVSymQ (Total Score) at 8 Weeks","description":"The VVSymQ is a subset of the VEINES-Sym and consists of the 5 symptoms most relevant to patients. The raw score, which can range from 5 to 30, was transformed to a summary VVSymQ score that ranges from 0 (worst possible symptom health) to 100 (best symptom health) using the following formula: VVSymQ: (Transformed Score) = \\[(Raw Score) - 5\\] \\* 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"3.18"},{"groupId":"OG001","value":"30.7","spread":"3.04"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":38},"commonTop":["contusion","limb discomfort","pruritis","incision site hematoma","pain in extremity"]}}}